Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany.

Niklaus Meier Hendrik Fuchs Katya Galactionova Cedric Hermans Mark Pletscher Matthias E Schwenkglenks

Published in: PharmacoEconomics - open (2024)

Depending on the price, ED can save costs and improve health outcomes of haemophilia patients compared with EHL-FIX prophylaxis, making it a potentially cost-effective alternative. These results are uncertain due to a lack of evidence regarding the long-term effectiveness of ED.

Keyphrases

emergency department
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
randomized controlled trial
systematic review
prognostic factors
peritoneal dialysis
high intensity
early onset
patient reported outcomes